Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan

Chin Hsiao Tseng, Yung-Kai Huang, Ya-Li Huang, Chi Jung Chung, Mo Hsiung Yang, Chien Jen Chen, Yu-Mei Hsueh

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

Long-term exposure to ingested inorganic arsenic is associated with peripheral vascular disease (PVD) in the blackfoot disease (BFD)-hyperendemic area in Taiwan. This study further examined the interaction between arsenic exposure and urinary arsenic speciation on the risk of PVD. A total of 479 (220 men and 259 women) adults residing in the BFD-hyperendemic area were studied. Doppler ultrasound was used to diagnose PVD. Arsenic exposure was estimated by an index of cumulative arsenic exposure (CAE). Urinary levels of total arsenic, inorganic arsenite (AsIII) and arsenate (AsV), monomethylarsonic acid (MMAV), and dimethylarsinic acid (DMA V) were determined. Primary methylation index [PMI = MMA V/(AsIII + AsV)] and secondary methylation index (SMI = DMAV/MMAV) were calculated. The association between PVD and urinary arsenic parameters was evaluated with consideration of the interaction with CAE and the confounding effects of age, sex, body mass index, total cholesterol, triglycerides, cigarette smoking, and alcohol consumption. Results showed that aging was associated with a diminishing capacity to methylate inorganic arsenic and women possessed a more efficient arsenic methylation capacity than men did. PVD risk increased with a higher CAE and a lower capacity to methylate arsenic to DMAV. The multivariate-adjusted odds ratios for CAE of 0, 0.1-15.4, and >15.4 mg/L × year were 1.00, 3.41 (0.74-15.78), and 4.62 (0.96-22.21), respectively (P <0.05, trend test); and for PMI ≤ 1.77 and SMI > 6.93, PMI > 1.77 and SMI > 6.93, PMI > 1.77 and SMI ≤ 6.93, and PMI ≤ 1.77 and SMI ≤ 6.93 were 1.00, 2.93 (0.90-9.52), 2.85 (1.05-7.73), and 3.60 (1.12-11.56), respectively (P <0.05, trend test). It was concluded that individuals with a higher arsenic exposure and a lower capacity to methylate inorganic arsenic to DMAV have a higher risk of developing PVD in the BFD-hyperendemic area in Taiwan.

Original languageEnglish
Pages (from-to)299-308
Number of pages10
JournalToxicology and Applied Pharmacology
Volume206
Issue number3
DOIs
Publication statusPublished - Aug 15 2005

Fingerprint

Peripheral Vascular Diseases
Arsenic
Taiwan
Methylation
Cacodylic Acid
Doppler Ultrasonography
Dynamic mechanical analysis
Tobacco Products
Alcohol Drinking

Keywords

  • Arsenic exposure
  • Peripheral vascular disease
  • Urinary arsenic speciation

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. / Tseng, Chin Hsiao; Huang, Yung-Kai; Huang, Ya-Li; Chung, Chi Jung; Yang, Mo Hsiung; Chen, Chien Jen; Hsueh, Yu-Mei.

In: Toxicology and Applied Pharmacology, Vol. 206, No. 3, 15.08.2005, p. 299-308.

Research output: Contribution to journalArticle

Tseng, Chin Hsiao ; Huang, Yung-Kai ; Huang, Ya-Li ; Chung, Chi Jung ; Yang, Mo Hsiung ; Chen, Chien Jen ; Hsueh, Yu-Mei. / Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. In: Toxicology and Applied Pharmacology. 2005 ; Vol. 206, No. 3. pp. 299-308.
@article{7237659c0d9f43dbab7b6666b4576197,
title = "Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan",
abstract = "Long-term exposure to ingested inorganic arsenic is associated with peripheral vascular disease (PVD) in the blackfoot disease (BFD)-hyperendemic area in Taiwan. This study further examined the interaction between arsenic exposure and urinary arsenic speciation on the risk of PVD. A total of 479 (220 men and 259 women) adults residing in the BFD-hyperendemic area were studied. Doppler ultrasound was used to diagnose PVD. Arsenic exposure was estimated by an index of cumulative arsenic exposure (CAE). Urinary levels of total arsenic, inorganic arsenite (AsIII) and arsenate (AsV), monomethylarsonic acid (MMAV), and dimethylarsinic acid (DMA V) were determined. Primary methylation index [PMI = MMA V/(AsIII + AsV)] and secondary methylation index (SMI = DMAV/MMAV) were calculated. The association between PVD and urinary arsenic parameters was evaluated with consideration of the interaction with CAE and the confounding effects of age, sex, body mass index, total cholesterol, triglycerides, cigarette smoking, and alcohol consumption. Results showed that aging was associated with a diminishing capacity to methylate inorganic arsenic and women possessed a more efficient arsenic methylation capacity than men did. PVD risk increased with a higher CAE and a lower capacity to methylate arsenic to DMAV. The multivariate-adjusted odds ratios for CAE of 0, 0.1-15.4, and >15.4 mg/L × year were 1.00, 3.41 (0.74-15.78), and 4.62 (0.96-22.21), respectively (P <0.05, trend test); and for PMI ≤ 1.77 and SMI > 6.93, PMI > 1.77 and SMI > 6.93, PMI > 1.77 and SMI ≤ 6.93, and PMI ≤ 1.77 and SMI ≤ 6.93 were 1.00, 2.93 (0.90-9.52), 2.85 (1.05-7.73), and 3.60 (1.12-11.56), respectively (P <0.05, trend test). It was concluded that individuals with a higher arsenic exposure and a lower capacity to methylate inorganic arsenic to DMAV have a higher risk of developing PVD in the BFD-hyperendemic area in Taiwan.",
keywords = "Arsenic exposure, Peripheral vascular disease, Urinary arsenic speciation",
author = "Tseng, {Chin Hsiao} and Yung-Kai Huang and Ya-Li Huang and Chung, {Chi Jung} and Yang, {Mo Hsiung} and Chen, {Chien Jen} and Yu-Mei Hsueh",
year = "2005",
month = "8",
day = "15",
doi = "10.1016/j.taap.2004.11.022",
language = "English",
volume = "206",
pages = "299--308",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan

AU - Tseng, Chin Hsiao

AU - Huang, Yung-Kai

AU - Huang, Ya-Li

AU - Chung, Chi Jung

AU - Yang, Mo Hsiung

AU - Chen, Chien Jen

AU - Hsueh, Yu-Mei

PY - 2005/8/15

Y1 - 2005/8/15

N2 - Long-term exposure to ingested inorganic arsenic is associated with peripheral vascular disease (PVD) in the blackfoot disease (BFD)-hyperendemic area in Taiwan. This study further examined the interaction between arsenic exposure and urinary arsenic speciation on the risk of PVD. A total of 479 (220 men and 259 women) adults residing in the BFD-hyperendemic area were studied. Doppler ultrasound was used to diagnose PVD. Arsenic exposure was estimated by an index of cumulative arsenic exposure (CAE). Urinary levels of total arsenic, inorganic arsenite (AsIII) and arsenate (AsV), monomethylarsonic acid (MMAV), and dimethylarsinic acid (DMA V) were determined. Primary methylation index [PMI = MMA V/(AsIII + AsV)] and secondary methylation index (SMI = DMAV/MMAV) were calculated. The association between PVD and urinary arsenic parameters was evaluated with consideration of the interaction with CAE and the confounding effects of age, sex, body mass index, total cholesterol, triglycerides, cigarette smoking, and alcohol consumption. Results showed that aging was associated with a diminishing capacity to methylate inorganic arsenic and women possessed a more efficient arsenic methylation capacity than men did. PVD risk increased with a higher CAE and a lower capacity to methylate arsenic to DMAV. The multivariate-adjusted odds ratios for CAE of 0, 0.1-15.4, and >15.4 mg/L × year were 1.00, 3.41 (0.74-15.78), and 4.62 (0.96-22.21), respectively (P <0.05, trend test); and for PMI ≤ 1.77 and SMI > 6.93, PMI > 1.77 and SMI > 6.93, PMI > 1.77 and SMI ≤ 6.93, and PMI ≤ 1.77 and SMI ≤ 6.93 were 1.00, 2.93 (0.90-9.52), 2.85 (1.05-7.73), and 3.60 (1.12-11.56), respectively (P <0.05, trend test). It was concluded that individuals with a higher arsenic exposure and a lower capacity to methylate inorganic arsenic to DMAV have a higher risk of developing PVD in the BFD-hyperendemic area in Taiwan.

AB - Long-term exposure to ingested inorganic arsenic is associated with peripheral vascular disease (PVD) in the blackfoot disease (BFD)-hyperendemic area in Taiwan. This study further examined the interaction between arsenic exposure and urinary arsenic speciation on the risk of PVD. A total of 479 (220 men and 259 women) adults residing in the BFD-hyperendemic area were studied. Doppler ultrasound was used to diagnose PVD. Arsenic exposure was estimated by an index of cumulative arsenic exposure (CAE). Urinary levels of total arsenic, inorganic arsenite (AsIII) and arsenate (AsV), monomethylarsonic acid (MMAV), and dimethylarsinic acid (DMA V) were determined. Primary methylation index [PMI = MMA V/(AsIII + AsV)] and secondary methylation index (SMI = DMAV/MMAV) were calculated. The association between PVD and urinary arsenic parameters was evaluated with consideration of the interaction with CAE and the confounding effects of age, sex, body mass index, total cholesterol, triglycerides, cigarette smoking, and alcohol consumption. Results showed that aging was associated with a diminishing capacity to methylate inorganic arsenic and women possessed a more efficient arsenic methylation capacity than men did. PVD risk increased with a higher CAE and a lower capacity to methylate arsenic to DMAV. The multivariate-adjusted odds ratios for CAE of 0, 0.1-15.4, and >15.4 mg/L × year were 1.00, 3.41 (0.74-15.78), and 4.62 (0.96-22.21), respectively (P <0.05, trend test); and for PMI ≤ 1.77 and SMI > 6.93, PMI > 1.77 and SMI > 6.93, PMI > 1.77 and SMI ≤ 6.93, and PMI ≤ 1.77 and SMI ≤ 6.93 were 1.00, 2.93 (0.90-9.52), 2.85 (1.05-7.73), and 3.60 (1.12-11.56), respectively (P <0.05, trend test). It was concluded that individuals with a higher arsenic exposure and a lower capacity to methylate inorganic arsenic to DMAV have a higher risk of developing PVD in the BFD-hyperendemic area in Taiwan.

KW - Arsenic exposure

KW - Peripheral vascular disease

KW - Urinary arsenic speciation

UR - http://www.scopus.com/inward/record.url?scp=22544460259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22544460259&partnerID=8YFLogxK

U2 - 10.1016/j.taap.2004.11.022

DO - 10.1016/j.taap.2004.11.022

M3 - Article

C2 - 16039941

AN - SCOPUS:22544460259

VL - 206

SP - 299

EP - 308

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 3

ER -